Interleukin-6 (IL-6) inhibitors are biologic therapies that block IL-6 signaling, a key pro-inflammatory pathway implicated in autoimmune diseases, chronic inflammation, and certain cancers.
Interleukin-6 (IL-6) inhibitors work through different mechanisms: anti-IL-6 receptor antibodies (tocilizumab, sarilumab), anti-IL-6 antibodies (siltuximab), and selective trans-signaling inhibitors.
IL-6 signals through two main pathways: classical signaling via membrane-bound IL-6 receptor, mediates protective and regenerative functions, while trans-signaling via soluble IL-6 receptor predominantly drives pathological inflammation.
Most current IL-6 inhibitors block both pathways, though selective trans-signaling inhibitors are in development.
Tocilizumab is a humanized monoclonal antibody against the IL-6 receptor, approved for rheumatoid arthritis, giant cell arteritis, polyarticular and systemic juvenile idiopathic arthritis, Castleman disease, and cytokine release syndrome.
It has demonstrated efficacy in DMARD-naïve patients and after DMARD or TNF inhibitor failure.
Sarilumab is another anti-IL-6 receptor antibody approved for rheumatoid arthritis, polymyalgia rheumatica, and polyarticular juvenile idiopathic arthritis.
Siltuximab directly neutralizes IL-6 cytokine itself and is approved specifically for multicentric Castleman disease.
Direct IL-6 blockade theoretically offers greater specificity than receptor blockade, as it doesn’t prevent other cytokines using the same receptor from signaling.
The main limitation of non-selective IL-6 inhibition is blocking both beneficial classical signaling and pathological trans-signaling, which may increase infection risk, hepatotoxicity, dyslipidemia, and rarely intestinal perforation.
Tocilizumab has a terminal half-life of approximately 16 days at therapeutic concentrations, and its effects cannot be reversed after administration.